A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J. Moran, Glenn D. Crater, David L. Bourdet, Nathan D. Pfeifer, Jacky Woo, Elad Kaufman, David A. Lombardi, Emily Y. Weng, Tuan Nguyen, Ashley Woodcock, Brett Haumann, Rajeev Saggar
Source: Eur Respir J, 58 (4) 2100673; 10.1183/13993003.00673-2021
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J. Moran, Glenn D. Crater, David L. Bourdet, Nathan D. Pfeifer, Jacky Woo, Elad Kaufman, David A. Lombardi, Emily Y. Weng, Tuan Nguyen, Ashley Woodcock, Brett Haumann, Rajeev Saggar. A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. Eur Respir J, 58 (4) 2100673; 10.1183/13993003.00673-2021
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Phase 1 demonstrates LYT-100 (deupirfenidone) is dose-proportional and well-tolerated when given twice-daily over multiple ascending doses (MAD) and shows a minor food effect (FE) Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001
Chronic inhalation toxicity study of nebulized alpha1 proteinase inhibitor (alpha1 -PI), TAL6005, in rodents Source: Annual Congress 2010 - Models of airways disease Year: 2010
Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, provides effective bronchodilation when administered by dry powder inhaler in COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
No-effect doses for effects on growth velocity (GV) in children receiving corticosteroids (CS) Source: Eur Respir J 2003; 22: Suppl. 45, 310s Year: 2003
High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1 Source: ERJ Open Res, 6 (4) 00395-2020; 10.1183/23120541.00395-2020 Year: 2020
Late Breaking Abstract - RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
Roflumilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002